CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2025.
Drug data last refreshed 3h ago · AI intelligence enriched 5d ago
CARBON DIOXIDE, USP is an inhaled gas formulation approved as a radiographic contrast agent that functions through X-ray contrast activity to enhance diagnostic imaging. It is indicated for use in contrast-enhanced imaging procedures where visualization of anatomical structures is clinically necessary. The product leverages CO2's low solubility and rapid absorption to provide real-time imaging enhancement with minimal systemic retention.
As a recently launched diagnostic agent with minimal current market penetration (0 linked jobs), early-stage commercialization teams are building infrastructure for niche imaging specialists.
X-Ray Contrast Activity
Radiographic Contrast Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on CARBON DIOXIDE, USP represents a ground-floor opportunity in a niche diagnostic franchise with early market development phases ahead. The specialized imaging market and recent approval create roles focused on clinical adoption, provider education, and payer engagement rather than large-scale primary care commercialization.